Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Ductal Carcinoma In Situ (DCIS) Clinical Trials

A listing of Ductal Carcinoma In Situ (DCIS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01439711?term=CALGB+40903&rank=1

Phase

A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure

This study aims to discover more about radiation techniques for people treated for left-sided breast cancer that minimizes exposure to the heart, as noted by mean heart dose. Both prone (lying face down) radiation and DIBH (Deep Inspiration Breath Hold) are more labor-intensive and usually require longer treatment times for ...

Phase

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

PRIMARY OBJECTIVES: I. To determine if treatment with a combination of metformin and doxycycline can increase the percentage of cells that express Caveolin-1 in the cancer associated fibroblasts of patients with breast, or uterine, and cervical cancers. SECONDARY OBJECTIVES: I. To determine the effect of metformin and doxycycline treatment on ...

Phase

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

PRIMARY OBJECTIVES: I. To demonstrate that 2 mg once daily per breast of 4-hydroxytamoxifen (4-OHT) topical gel results in a reduction in the Ki-67 labeling index of ductal breast carcinoma in situ (DCIS) lesions that is not inferior to that seen with 20 mg daily oral tamoxifen citrate (TAM) for ...

Phase

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Phase

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

Currently, the rate of ipsilateral breast tumor recurrence (IBTR) after breast- conserving surgery and radiotherapy remains at 10% at 10 years to 15% at 20 years, respectively. IBTR is an independent predictor of poor survival with a 3 to 4.6 increased risk of cancer-related death. In a heterogeneous population, local ...

Phase

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

OBJECTIVES There are two study components, 1) to evaluate the treatment response and toxicity of the protocol, and 2) to investigate the role of Magnetic Resonance Imaging (MRI) to monitor and predict the final pathological response. Objectives for treatment study component: 1.1 To estimate 2-year progression-free survival in patients with ...

Phase

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Advances in early detection techniques and improvement in systemic treatment of early stage breast cancer have led to a small decline in overall breast cancer mortality in the last 20 years. New advances will require understanding of breast cancer biology at the molecular level. Inhibition of COX-2 and its analysis ...

Phase

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) ...

Phase

The PROMISE Study: Duavee in Women With DCIS

PRIMARY OBJECTIVES; To determine if CE/BZA reduces proliferation as measured by Ki-67 protein expression Secondary Objectives: To determine if CE/BZA modulates expression of ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). To determine if CE/BZA modulates a previously validated set of epithelial markers of progression. To ...

Phase